Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia

The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (VEN) in combination with lower-intensity therapy is an efficacious treatment for acute myeloid leukemia (AML). VEN in combination with the hypomethylating agent azacitidine improved rates of response and measurable residual disease (MRD)-negative r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lachowiez, Curtis A., Atluri, Himachandana, DiNardo, Courtney D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058453/
https://www.ncbi.nlm.nih.gov/pubmed/35510212
http://dx.doi.org/10.1177/20406207221093964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058453/
https://www.ncbi.nlm.nih.gov/pubmed/35510212
http://dx.doi.org/10.1177/20406207221093964

Ejemplares similares